CardioRoot Post-Marketing Surveillance Registry (CardioRoot)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Olomouc, Czechia, 775 20
- University Hospital Olomouc
-
Prague, Czechia, 128 08
- General University Hospital
-
Prague, Czechia, 150 06
- University Hospital Motol
-
-
-
-
-
Bordeaux, France, 33404
- Centre Hospitalier Universitaire (CHU) de Bordeaux
-
-
-
-
-
Lecco, Italy, 23900
- Ospedale Manzoni di Lecco
-
Milano, Italy, 20157
- Ospedale Luigi Sacco
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- patients requiring a CardioRoot graft as per the CardioRoot Instructions for Use (IFU)
Exclusion Criteria:
- patients with contra-indications per CardioRoot IFU
- patients requiring consecutive aortic surgery
- patients with coronary artery disease
- patients who require urgent or emergent surgery
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
CardioRoot
All subjects receive the CardioRoot graft at baseline implant procedure.
|
prospective single arm multi-center study to evaluate CardioRoot grafts implanted in a thoracic position.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Graft complications
Time Frame: 30 days
|
Complications will be assessed out to one year post implantation.
|
30 days
|
|
Graft complications
Time Frame: 1 year
|
Complications will be assessed out to one year post implantation.
|
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Subject mortality rate
Time Frame: 30 days, 1 year
|
Subject mortality rate will be followed out to one year post implantation.
|
30 days, 1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- MCV00008317
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.